Conjugating polysaccharide capsule antigen to a protein conjugate (like diphtheria or tetanus toxoid) enhances immunogenicity by enabling T-cell activation, leading to a stronger immune response, as seen in Pneumovax (PCV13), Hib, and Meningococcal vaccines.
Polisakkarit kapsül antijenini protein konjugatı (difteri veya tetanoz protein toksidi) ile konjüge etmek, T hücre aktivasyonuna yol açarak daha güçlü bir immün yanıt oluşturur ve bu, Pnevomaks (PCV13), Hib ve Menengokokal aşılarda görülür.
| Front | What is the benefit of conjugating polysaccharide capsule Ag to protein conjugate (diphtheria | tetanus protein toxoid) → (3) examples? |
|---|---|
| Back | Immunogenic protein causes T-cell activation that leads to co-activation of B-cells → stronger response to antigen that T cell independent activation ↓ Isotype switching Somatic hypermutation Memory B-cell formation Hib Meningococcal vaccine |
Tags: antimicrobial, drugs
Learn with these flashcards. Click next, previous, or up to navigate to more flashcards for this subject.
Next card: N.meningitidis drugs used chemoprophylaxis rifampin meningococcal prophylaxis penetrating
Previous card: Amphotericin b moa side effects systemic mycoses histoplasmosis
Up to card list: Microbiology 101 → Step 1 USMLE